Ipsen CBO: We Are Seeking Fresh Rare Disease Buys
“Externalization” Needed To Re-Fill Its Maturing Pipeline
Ipsen’s chief business officer tells Scrip that buying Canada’s Clementia Pharmaceuticals this year gave the French group’s rare disease operations an “anchor asset” to build on.
